Pharmacokinetics of Arsenic Hexaoxide, a Anticancer Compound, in Rats
![]() |
Lee, Pung-Sok
(National Research Laboratory of PK/PD, CBITRC, College of Pharmacy, Chungbuk National University)
Shin, Dae-Hwan (National Research Laboratory of PK/PD, CBITRC, College of Pharmacy, Chungbuk National University) Lee, So-Young (National Research Laboratory of PK/PD, CBITRC, College of Pharmacy, Chungbuk National University) Lee, Jung-Yeol (National Research Laboratory of PK/PD, CBITRC, College of Pharmacy, Chungbuk National University) Lee, Kyoung-Mi (National Research Laboratory of PK/PD, CBITRC, College of Pharmacy, Chungbuk National University) Kwon, Koo-Hyun (National Research Laboratory of PK/PD, CBITRC, College of Pharmacy, Chungbuk National University) Chung, Youn-Bok (National Research Laboratory of PK/PD, CBITRC, College of Pharmacy, Chungbuk National University) |
1 | H. Chen, R.C. MacDonald, S. Li, N.L. Krett, S.T. Rosen and T.V. O'Halloran, Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for aontrolled anticancer drug release, J. Am. Chem. Soc., 128, 13348-13349 (2006) DOI ScienceOn |
2 | M. Baumgartner, S. Sturlan, E. Roth, B. Wessner and T. Bachleitner-Hofmann, Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells, Int. J. Cancer, 112, 707-712 (2004) DOI ScienceOn |
3 | M.F. Hughes, L.M. Del Razo and E.M. Kenyon, Dose-dependent effects on tissue distribution and metabolism of dimethylarsinic acid in the mouse after intravenous admini-stration, Toxicology, 21, 155-166 (2000) |
4 | Marie Vahter, Mechanism of arsenic biotransformation, Toxicology, 27, 211-217 (2002) |
5 | L. Luo, H. Qiao, F. Meng, X. Dong, B. Zhou, H. Jiang, J.R. Kanwar, G.W. Krissansen and X. Sun, Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas, Int. J. Cancer, 118, 1823-1830 (2006) DOI ScienceOn |
6 | K.B. Kim, A.Y. Bedikian, L.H. Camacho, N.E. Papado- poulos and C. McCullough, A phase II Trial of arsenic trioxide in patients with metastatic melanoma, Cancer, 104, 1687-1692 (2005) DOI ScienceOn |
7 | M.T. Rojewski, S. Korper and H. Schrezenmeier, Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to beside, Leuk. Lymphoma, 45, 2387-2401 (2004) DOI ScienceOn |
8 | M. Styblo and D.J. Thomas, Selenium modifies the meta- bolism and toxicity of arsenic in primary rat hepatocytes, Toxicol. Appl. Pharmacol., 172, 52-61 (2001) DOI ScienceOn |
9 | C.A. Loffredo, H.V. Aposhian, M.E. Cebrian, H. Yamauchi and E.K. Silbergeld, Variability in human metabolism of arsenic, Environ. Res., 92, 85-91 (2003) DOI ScienceOn |
10 | M. Vahter, Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity, Toxicol. Lett., 15, 209-217 (2000) |
11 | H. Maeda, S. Hori, H. Ohizumi, T. Segawa, Y. Kakehi, O. Ogawa and A. Kakizuka, Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine, Cell Death Differ., 11, 737-746 (2004) DOI ScienceOn |
12 | S. Fujisawa, R. Ohno, K. Shigeno, N. Sahara, S. Nakamura, K. Naito, M. Kobayashi, K. Shinjo, A. Takeshita, Y. Suzuki, H. Hashimoto, K. Kinoshita, M. Shimoya, T. Kaise and K. Ohnishi, Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide, Cancer Chemother. Pharmacol. (2006) |
13 | Z. gong, X, Lu, M. Ma, C. Waat and X.C. Le, Arsenic speciation analysis, Talanta, 58, 77-96 (2002) DOI ScienceOn |
14 | Y. Fukai, M. Hirata, M. Ueno, N. Ichikawa, H. Kobayashi, H. Saitoh, T. Sakurai, K. Kinoshita, T. Kaise and S. Ohta, Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine, Biol. Pharm. Bull., 29, 1022-1027 (2006) DOI ScienceOn |
15 | K. Ishitsuka, A. Shirahashi, Y. Iwao, M. Shishime, Y. Takamatsu, Y. Takatsuka, A. Utsunomiya, J. Suzumiya, S. Hara and K. Tamura, Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide, Eur. J. Haematol., 72, 280-284 (2004) DOI ScienceOn |
16 | I. Csanaky and Z. Gregus, Species variations in the biliary and urinary excretion of arsenate, arsenite and their meta- bolites, Comp. Biochem. Physiol. C. Toxicol. Pharmacol., 131, 355-365 (2001) DOI ScienceOn |
17 | W.C. Chou and C.V. Dang, Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies, Curr. Opin. Hematol., 12, 1-6 (2005) DOI ScienceOn |
18 | C.J. Lin, M.H. Wu, Y.M. Hsueh, S.S. Sun and A.L Cheng, Tissue distribution of arsenic species in rabbits after single and multiple paranteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective, Cancer Chemother. Pharmacol., 55, 170-178 (2005) DOI |
![]() |